Dinaciclib enhances natural killer cell cytotoxicity against acute myelogenous leukemia

Blood Adv. 2019 Aug 27;3(16):2448-2452. doi: 10.1182/bloodadvances.2019000064.

Abstract

  1. Dinaciclib enhances NK-cell activity against leukemia cells in preclinical AML models.

  2. Enhanced NK-cell activation by dinaciclib-treated AML is associated with downregulation of inhibitory NK ligand HLA-E on leukemia cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Cell Line, Tumor
  • Cyclic N-Oxides
  • Cytotoxicity, Immunologic / drug effects*
  • Disease Models, Animal
  • Humans
  • Immunomodulation / drug effects*
  • Immunophenotyping
  • Indolizines
  • Killer Cells, Natural / drug effects*
  • Killer Cells, Natural / immunology*
  • Killer Cells, Natural / metabolism
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / immunology*
  • Leukemia, Myeloid, Acute / metabolism
  • Lymphocyte Activation / drug effects
  • Lymphocyte Activation / immunology
  • Mice
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridinium Compounds / pharmacology*
  • Pyridinium Compounds / therapeutic use
  • Xenograft Model Antitumor Assays

Substances

  • Biomarkers
  • Bridged Bicyclo Compounds, Heterocyclic
  • Cyclic N-Oxides
  • Indolizines
  • Protein Kinase Inhibitors
  • Pyridinium Compounds
  • dinaciclib